Modality
Bispecific Ab
MOA
SOS1i
Target
SOS1
Pathway
mTOR
CKDEndometrial CaPsoriasis
Development Pipeline
Preclinical
Jan 2018
→ Mar 2026
PreclinicalCurrent
NCT05621676
520 pts·Psoriasis
2018-01→2025-04·Not yet recruiting
NCT06248243
1,439 pts·Psoriasis
2019-02→2026-03·Terminated
1,959 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-04-1312mo agoInterim· Psoriasis
2026-03-034w agoInterim· Psoriasis
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Preclinical
Not yet…
Preclinical
Termina…
Catalysts
Interim
2025-04-13 · 12mo ago
Psoriasis
Interim
2026-03-03 · 4w ago
Psoriasis
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05621676 | Preclinical | Psoriasis | Not yet recr... | 520 | 6MWD |
| NCT06248243 | Preclinical | Psoriasis | Terminated | 1439 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 |